e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 1.53% | -3.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.53% | -3.16% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 1.53% | -3.16% | |||
| SG&A Expenses | 1.48% | 11.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.48% | -3.97% | |||
| Operating Income | -1.48% | 3.99% | |||
| Income Before Tax | -1.49% | 4.61% | |||
| Income Tax Expenses | -1.49% | 16.98% | |||
| Earnings from Continuing Operations | -1.48% | 2.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.48% | 2.32% | |||
| EBIT | -1.48% | 3.99% | |||
| EBITDA | -2.67% | 1.77% | |||
| EPS Basic | -1.72% | 4.92% | |||
| Normalized Basic EPS | -2.38% | 8.70% | |||
| EPS Diluted | -1.72% | 4.92% | |||
| Normalized Diluted EPS | -2.38% | 8.70% | |||
| Average Basic Shares Outstanding | 0.00% | 2.65% | |||
| Average Diluted Shares Outstanding | 0.00% | 2.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||